Dunad
Cambridge, GB · Founded 2020 · 12 employees on LinkedIn · 3 known investors
Find your way into Dunad
192 people in our graph share verified history with the Dunad team — schools, employers, funds. One of them is your warm intro.
Sam Blackmanunlockedknows Pearl Huang · together at GSK (overlapped)
×10knows the team · via GSK
knows the team · via Cygnal Therapeutics
Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.
Founders & leadership
PH
Pearl HuanginPresident & CEOPearl Huang is President and CEO of Dunad Therapeutics, a biotech company developing oral small-molecule medicines for neurodegenerative diseases. She holds an S.B. in Life Sciences from MIT and a Ph.D. in Molecular Biology from Princeton University, and serves as an Independent Director at Waters and Non-Executive Director at BB Biotech.
SH
Stephen HuhnCMO
Investors · 3
In the news
Frequently asked questions
- What does Dunad do?
- Dunad Therapeutics is a biotech company developing oral small-molecule medicines using a covalent chemistry discovery platform to target neurodegenerative diseases such as ALS, Parkinson's disease, and FTD. Its programs aim to clear disease-driving proteins like toxic TDP43 to slow disease progression for patients and their families.
- Who are Dunad's investors?
- Dunad's investors include BGV, Alpha Wave Global, Epidarex Capital.
- Where is Dunad headquartered?
- Dunad is headquartered in Cambridge, GB.